Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus in platinum-refractory ovarian cancer or advanced endometrial cancer
2011-000299-33Phase 2Completed
- Sponsor
- AGO Research
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in ovarian cancer and endometrial cancer (EC) (2 arms), sponsored by AGO Research. Primary endpoints: Progression-free survival rate at 4 months (ovarian cancer cohort) and Progression-free survival rate at 6 months (endometrial cancer cohort). Started Jun 2011; status: completed.
02
Drugs
temsirolimus
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on 2011-000299-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000299-33.